Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
50 Results for "
viruse
" in MedChemExpress (MCE) Product Catalog:
Products (50)
50 Results for "viruse" in MCE Product Catalog:
Cat. No.: HY-P81562
Synonyms: C3DR antibody;
CD 21 antibody;
CD21 antibody;
Complement C3d receptor antibody;
Complement component (3d/Epstein Barr virus) receptor 2 antibody;
Complement receptor type 2 antibody;
CR antibody;
Cr2 antibody;
CR2_HUMAN antibody;
CVID7 antibody;
EBV receptor antibody;
EBV-R antibody;
Epstein Barr virus receptor antibody;
Epstein-Barr virus receptor antibody;
EVBR antibody;
SLEB9 antibody;
Cat. No.: HY-178455
CAS No.: 3031321-95-3
Target:
Research Areas:
Influenza virus-IN-10 is a dual-target antiviral agents for influenza that targets both PAC (KD = 8.9 μM) and NP (KD = 52.5 μM) simultaneously. Influenza virus-IN-10 exhibits an EC50 values of 1.64 μM) against influenza A virus (H1N1, A/WSN/33) and broad-spectrum activity against other influenza strains, including influenza B virus and multiple subtypes of influenza A .
Cat. No.: HY-180162
CAS No.: 2781933-70-6
Target:
Research Areas:
Influenza A virus-IN-17 (Compound 6a) is a potent influenza A inhibitor with EC90s of 3.5 μM and 2.6 μM for H3N2 and H1N1, respectively. Influenza A virus-IN-17 inhibits U2-PB2 chimeric mRNA (EC90 = 2.1 μM from cap snatching polymerase) .
Cat. No.: HY-180933
Target:
Research Areas:
Monkeypox virus resolvase-IN-1 (compound 5-1) is a potent monkeypox virus resolvase (Mpr) inhibitor with an IC50 of 36 nM. Monkeypox virus resolvase-IN-1 exhibits antiviral activity in vaccinia virus (VACV), a model orthopoxvirus, with an EC50 of 3.2 nM. Monkeypox virus resolvase-IN-1 can be used for antiviral research .
Cat. No.: HY-181785
CAS No.: 3085746-63-7
Target:
Research Areas:
Influenza A virus-IN-18 (Compound C2e) is an orally active inhibitor of Influenza A virus (IC50: 2.5 μM against PR8/H1N1; 6.42 μM against H3N2). Influenza A virus-IN-18 binds directly to the H1N1/PR8 HA protein with high affinity, with a KD of 0.25 μM. Influenza A virus-IN-18 is applicable to research related to Influenza A virus infection .
Cat. No.: HY-182895
CAS No.: 3027187-19-2
Target:
Research Areas:
Influenza A virus-IN-19 (Compound (S)-63) is an orally active, selective Influenza A virus inhibitor with an EC50 of 0.44 μM. Influenza A virus-IN-19 exhibits moderate binding affinity to Hemagglutinin, with a Kd of 5.66 μM. Influenza A virus-IN-19 inhibits trypsin-mediated cleavage of HA0, blocks the early viral entry process, and suppresses the replication of Influenza A virus. Influenza A virus-IN-19 improves the survival rate of mice in lethal influenza models. Influenza A virus-IN-19 can be used in studies related to Influenza A virus infection .
Cat. No.: HY-P5477
CAS No.: 152647-29-5
Target:
Research Areas:
Cat. No.: HY-P79151A
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Genome polyprotein; Tobacco Etch Virus Protease
Species:
Virus
Source:
E. coli
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
